AU2012258575B2 - Pirfenidone and anti-fibrotic therapy in selected patients - Google Patents

Pirfenidone and anti-fibrotic therapy in selected patients Download PDF

Info

Publication number
AU2012258575B2
AU2012258575B2 AU2012258575A AU2012258575A AU2012258575B2 AU 2012258575 B2 AU2012258575 B2 AU 2012258575B2 AU 2012258575 A AU2012258575 A AU 2012258575A AU 2012258575 A AU2012258575 A AU 2012258575A AU 2012258575 B2 AU2012258575 B2 AU 2012258575B2
Authority
AU
Australia
Prior art keywords
pirfenidone
fvc
receptor
limited
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012258575A
Other languages
English (en)
Other versions
AU2012258575A1 (en
Inventor
Williamson Ziegler Bradford
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intermune Inc
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of AU2012258575A1 publication Critical patent/AU2012258575A1/en
Application granted granted Critical
Publication of AU2012258575B2 publication Critical patent/AU2012258575B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2012258575A 2011-05-25 2012-05-25 Pirfenidone and anti-fibrotic therapy in selected patients Ceased AU2012258575B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201161489936P 2011-05-25 2011-05-25
US61/489,936 2011-05-25
US201161490057P 2011-05-26 2011-05-26
US61/490,057 2011-05-26
US201161523047P 2011-08-12 2011-08-12
US61/523,047 2011-08-12
US201161524961P 2011-08-18 2011-08-18
US61/524,961 2011-08-18
PCT/US2012/039538 WO2012162592A1 (en) 2011-05-25 2012-05-25 Pirfenidone and anti-fibrotic therapy in selected patients

Publications (2)

Publication Number Publication Date
AU2012258575A1 AU2012258575A1 (en) 2013-11-21
AU2012258575B2 true AU2012258575B2 (en) 2017-03-02

Family

ID=47217770

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012258575A Ceased AU2012258575B2 (en) 2011-05-25 2012-05-25 Pirfenidone and anti-fibrotic therapy in selected patients

Country Status (11)

Country Link
US (1) US20150164874A1 (https=)
EP (1) EP2713732A4 (https=)
JP (1) JP6170040B2 (https=)
KR (1) KR20140022048A (https=)
AU (1) AU2012258575B2 (https=)
CA (1) CA2835438A1 (https=)
HK (1) HK1197159A1 (https=)
IL (1) IL229226A0 (https=)
MX (1) MX2013013752A (https=)
SG (1) SG195110A1 (https=)
WO (1) WO2012162592A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008157786A1 (en) 2007-06-20 2008-12-24 Auspex Pharmaceutical, Inc. Substituted n-aryl pyridinones as fibrotic inhibitors
JP2014507474A (ja) * 2011-03-08 2014-03-27 オースペックス・ファーマシューティカルズ・インコーポレイテッド 置換ｎ−アリールピリジノン
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
EP3782604A1 (en) * 2013-07-31 2021-02-24 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
MX382781B (es) 2014-04-02 2025-03-13 Intermune Inc Piridinonas anti-fibroticas.
EP3194446B1 (en) * 2014-09-18 2022-10-26 Cedars-Sinai Medical Center Compositions and methods for treating fibrosis
ES2764840T3 (es) * 2015-01-28 2020-06-04 Univ Bordeaux Uso de plerixafor para tratar y/o prevenir exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica
US20180064662A1 (en) * 2015-03-05 2018-03-08 The General Hospital Corporation Novel compositions and uses of metformin agents
WO2018167103A1 (en) * 2017-03-13 2018-09-20 Genfit Pharmaceutical compositions for combination therapy
AU2018322475A1 (en) * 2017-08-22 2020-03-05 Biogen Ma Inc. Pharmaceutical compositions and dosage regimens containing anti-alpha(v)beta(6) antibodies
EP3969033A4 (en) * 2019-05-17 2023-06-14 The Regents of the University of California MPS-MODIFIED PEPTIDES AND THEIR USE
CN112239507A (zh) 2019-07-17 2021-01-19 鸿运华宁（杭州）生物医药有限公司 ETA抗体与TGF-β Trap的融合蛋白质，以及其药物组合物和应用
EP3821946A1 (en) * 2019-11-12 2021-05-19 Université de Strasbourg Anti-claudin-1 monoclonal antibodies for the prevention and treatment of fibrotic diseases
JP7665619B2 (ja) 2019-12-04 2025-04-21 イドルシア・ファーマシューティカルズ・リミテッド 線維性疾患の治療に使用するためのアゼチジンｌｐａ１受容体アンタゴニストのピルフェニドン及び／又はニンテダニブとの合剤
CA3171622A1 (en) * 2020-03-13 2021-09-16 Puretech Lyt 100, Inc. Methods of treating respiratory disease with deupirfenidone
CN114617890A (zh) * 2020-12-08 2022-06-14 四川夏派森医药科技有限公司 DH404在治疗SARS-CoV-2感染中的应用
CN112640887B (zh) * 2020-12-25 2022-05-13 武汉睿健医药科技有限公司 一种神经干细胞冻存液及其应用
WO2022266370A1 (en) * 2021-06-17 2022-12-22 Aria Pharmaceuticals, Inc. Sparsentan for treating idiopathic pulmonary fibrosis
CN114097807B (zh) * 2021-11-25 2023-05-05 兰州大学 巴多索隆类化合物在抗农业病原真菌中的用途
JP2025511066A (ja) * 2022-03-31 2025-04-15 ピュアテック・エル・ワイ・ティ・１００・インコーポレイテッド デューピルフェニドンにより間質性肺疾患ならびに他の線維化介在性肺疾患及び障害を治療する方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005110478A2 (en) * 2004-04-13 2005-11-24 Intermune, Inc. Combination therapy for treating fibrotic disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1258484E (pt) * 2000-02-18 2009-04-03 Kyowa Hakko Kirin Co Ltd Novos compostos de isoxazol e de tiazol e sua utilização enquanto fármacos
JP2005531628A (ja) * 2002-06-28 2005-10-20 ジ アドミニストレイターズ オブ ザ チューレン エデュケイショナル ファンド 肺線維症の処置のための４−（４−メチルピペラジン−１−イルメチル）−ｎ−［４−メチル−３−（４−ピリジン−３−イル）ピリミジン−２−イルアミノ）フェニル］−ベンズアミド
WO2004103296A2 (en) * 2003-05-16 2004-12-02 Intermune, Inc. Methods of treating idiopathic pulmonary fibrosis
SG174050A1 (en) * 2006-04-13 2011-09-29 Actelion Pharmaceuticals Ltd Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
JP2010502224A (ja) * 2006-09-08 2010-01-28 アボット・ラボラトリーズ インターロイキン１３結合タンパク質
WO2008157786A1 (en) * 2007-06-20 2008-12-24 Auspex Pharmaceutical, Inc. Substituted n-aryl pyridinones as fibrotic inhibitors
AP2011005824A0 (en) * 2009-01-26 2011-08-31 Intermune Inc Methods for treating acute myocardial infarctions and associated disorders.
GB2474748B (en) * 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005110478A2 (en) * 2004-04-13 2005-11-24 Intermune, Inc. Combination therapy for treating fibrotic disorders

Also Published As

Publication number Publication date
IL229226A0 (en) 2014-01-30
JP2014518880A (ja) 2014-08-07
AU2012258575A1 (en) 2013-11-21
WO2012162592A1 (en) 2012-11-29
MX2013013752A (es) 2014-08-01
JP6170040B2 (ja) 2017-07-26
NZ617415A (en) 2017-07-28
EP2713732A1 (en) 2014-04-09
CA2835438A1 (en) 2012-11-29
US20150164874A1 (en) 2015-06-18
EP2713732A4 (en) 2014-12-03
SG195110A1 (en) 2013-12-30
HK1197159A1 (en) 2015-01-09
KR20140022048A (ko) 2014-02-21

Similar Documents

Publication Publication Date Title
AU2012258575B2 (en) Pirfenidone and anti-fibrotic therapy in selected patients
JP6532878B2 (ja) 組合せ医薬
EP2285366B1 (fr) Molecules inhibant une voie metabolique impliquant la proteine tyrosine kinase syk et procede d'identification de ces molecules
JP6695353B2 (ja) Ｆｇｆｒ４阻害剤としてのホルミル化ｎ−複素環式誘導体
JP2019532051A (ja) Ｒａｆ阻害剤及びｅｒｋ阻害剤を含む治療用組合せ
AU2019402151B2 (en) Combinations of a HDM2-p53 interaction inhibitor and a BCL2 inhibitor and their use for treating cancer
US11746103B2 (en) ALK-5 inhibitors and uses thereof
TW202517302A (zh) 穩定的、濃縮的放射性核種錯合物溶液
JP2012526772A (ja) ホスホイノシチド３−キナーゼ阻害剤および抗糖尿病性化合物の組合せ剤
WO2021216814A1 (en) Btk inhibitors to treat pulmonary distress in covid-19 patients
US20240197729A1 (en) ALK-5 Inhibitors and Uses Thereof
CN102895230A (zh) 包含噁唑化合物的抗结核组合物
JP7565132B2 (ja) がんの治療又は予防用医薬
NZ617415B2 (en) Pirfenidone and anti-fibrotic therapy in selected patients
US20250177352A1 (en) Combination treatment for cancer
McGowan et al. Drug-Drug Interaction Guide: From HIV Prevention to Treatment
JP2023177335A (ja) がん治療のための併用療法
Gras Avapritinib. PDGFR-alpha and KIT mutant inhibitor, Treatment of gastrointestinal stromal tumor, Treatment of systemic mastocytosis
HK40112852A (zh) 癌的治疗或预防用药物
Heist Phase II trial of cabozantinib (XL184) in patients with advanced solid (non-breast
HK1240076B (zh) 联用药物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired